Increased production of chemokines and cytokines by the immune system during COVID-19 also can harm pancreatic β cell function, instilling insulin-glucose-dependent dose sensitivity (Rubino et al., 2020; Li et al., 2020a; Kazakou et al., 2021). Here, INS is linked to COVID-19.